The PARITY Methods Centre team presented the PARITY trial update at the 29th Annual European Musculo-skeletal Oncology Society (EMSOS) Meeting in La Baule, France last week.
The meeting focused on Ewing sarcoma, margins, pelvic tumours, targeted therapy; open sessions offered the opportunity to report and discuss the latest results in all fields.
The PARITY trial is investigating whether long duration post-operative prophylactic antibiotics decreases the incidence of surgical site infections compared to the standard shorter duration among patients undergoing surgical excision and endoprosthetic reconstruction of lower extremity bone tumors. Led by Dr. Michelle Ghert, PARITY is the first rigorously designed trial in the field of orthopaedic oncology and has the potential to significantly impact clinical practice and establish a collaborative network worldwide for future research in the field. Prior to PARITY, orthopaedic oncologists doubted that prospective multi-center randomized trials were possible in their specialty. The success of the PARITY trial has demonstrated that these types of studies are, in fact, possible.